Nom du produit:2-nitro-5,6,8,9-tetrahydro-7H-benzo[7]annulen-7-one

IUPAC Name:2-nitro-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-one

CAS:740842-50-6
Formule moléculaire:C11H11NO3
Pureté:95%
Numéro de catalogue:CM153725
Poids moléculaire:205.21

Unité d'emballage Stock disponible Prix($) Quantité
CM153725-1g 1-2 Weeks ƙŴƻ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:740842-50-6
Formule moléculaire:C11H11NO3
Point de fusion:-
Code SMILES:O=C1CCC2=CC([N+]([O-])=O)=CC=C2CC1
Densité:
Numéro de catalogue:CM153725
Poids moléculaire:205.21
Point d'ébullition:
N° Mdl:MFCD11869793
Stockage:Store at room temperature.

Column Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Bemcentinib
Bemcentinib is a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. Extensive studies confirm the ability to combine bemcentinib with immune checkpoint inhibitors, chemotherapies and targeted therapies with the goal of improving a patient’s immune response and delaying the development of chemoresistance. Bemcentinib is currently being investigated in combination with immune checkpoint inhibition and chemotherapy in first line NSCLC patients harboring mutations in the STK11 gene, a known prognostic factor of poor response to existing therapies.

Related Products